New York Senate Bill S07562

New York 2025-2026 Regular Session

• Introduced: 4/22/25
• Refer: 4/22/25
• Refer: 1/7/26

Caption

Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains.

Summary

This bill would amend the Education Law to require prescription drug containers to include a physical description of the medication inside the container. In addition to the existing label information, pharmacies would have to list the drug’s size, shape, color, and imprint on the immediate container when dispensing a prescription drug. The bill applies to prescription drugs generally and does not change the rules for contact lenses, eyeglasses, or other vision-related devices excluded from the definition of drug under the statute. The measure would take effect 90 days after becoming law and would direct pharmacies to comply through existing labeling rules and regulations issued by the Commissioner of Health. In practical terms, it would add a new labeling requirement for pharmacists and pharmacies, likely affecting dispensing procedures, label design, and pharmacy workflow across the state.

Impact

The bill would amend section 6810 of the Education Law, which governs the dispensing and labeling of prescription drugs in New York. It would add a statutory requirement that prescription labels include a physical description of the drug—specifically its size, shape, color, and imprint—expanding the information that must appear on the container. Pharmacies and pharmacists would need to update labeling practices to comply, while the Commissioner of Health would retain authority to promulgate implementing rules. The bill does not alter controlled substance requirements or the existing exclusions for vision-related devices.

Sentiment

There is limited recorded legislative history for this bill, with no committee transcript or vote data available in the provided materials. Based on the bill text and caption, the measure appears to be framed as a patient-safety and medication-identification improvement, suggesting generally favorable intent. Because no debate or votes are included, there is no documented opposition or support to assess beyond the bill’s stated purpose.

Contention

The main policy issue is whether requiring physical descriptions on prescription labels would meaningfully improve safety and reduce medication errors, versus creating additional administrative burden for pharmacies. Potential concerns may include label space, workflow changes, and the practicality of describing certain medications consistently. Supporters would likely emphasize easier identification of pills for patients, caregivers, and pharmacists, especially in cases of multiple medications or packaging mix-ups. No specific opposing or supporting stakeholders are identified in the available record.